China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors

SHANGHAI - Nanjing, China's Simcere Pharmaceutical Group reported a slowdown in sales for the second quarter, pointing to intense competition from the spread of Anhui province's tender model for essential drugs and price cuts on products included in the National Drug Reimbursement List